By: Christina T. Loguidice
Investigators have achieved some success with immune checkpoint inhibitors and antiangiogenesis agents in patients with advanced gastroesophageal cancers, and exciting new agents targeting different tumor growth pathways are under investigation.
By: Jane de Lartigue, PhD
Cancer cells must maintain a delicate balance to prevent catastrophic levels of DNA damage from triggering cell death, and their heavy reliance on the remaining normal DNA damage response components creates a therapeutically targetable Achilles’ heel.
By: Andrew D. Smith
Although the need for biomarkers of immunotherapy response has generated much attention, investigators also are pursuing mechanisms for distinguishing which patients will experience adverse effects from these therapies.
By: David C. Fryefield, MD
Although some of the improvement is a result of prevention and screening, advances in technology and in chemotherapy and immunotherapy pharmaceuticals have been major driving forces in the decline in cancer-related death.
By: Jason Harris
Evidence continues to build that tucatinib, a novel small molecule HER2 inhibitor, is safe and effective for patients with advanced HER2-positive breast cancer in combination with standard therapies, including for those who develop brain metastases.